tradingkey.logo

PharmaCyte Biotech Inc

PMCB
0.890USD
-0.027-2.99%
Fechamento 11/04, 16:00ETCotações atrasadas em 15 min
6.05MValor de mercado
PerdaP/L TTM

PharmaCyte Biotech Inc

0.890
-0.027-2.99%

Mais detalhes de PharmaCyte Biotech Inc Empresa

PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.

Informações de PharmaCyte Biotech Inc

Código da empresaPMCB
Nome da EmpresaPharmaCyte Biotech Inc
Data de listagemSep 11, 2003
CEOMr. Joshua N. (Josh) Silverman
Número de funcionários2
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 11
Endereço3960 Howard Hughes Parkway, Suite 500
CidadeLAS VEGAS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal89169
Telefone19175952850
Sitehttps://pharmacyte.com/
Código da empresaPMCB
Data de listagemSep 11, 2003
CEOMr. Joshua N. (Josh) Silverman

Executivos da empresa PharmaCyte Biotech Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--

Detalhamento da receita

Sem dados
Sem dados
Por Empresa
Por Região
Sem dados

Distribuição de ações

Atualizado em: sáb, 25 de out
Atualizado em: sáb, 25 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Intracoastal Capital, L.L.C.
7.76%
The Vanguard Group, Inc.
2.86%
Geode Capital Management, L.L.C.
1.86%
Equitec Proprietary Markets, LLC
1.22%
Asher (Daniel B)
1.22%
Outro
85.08%
Investidores
Investidores
Proporção
Intracoastal Capital, L.L.C.
7.76%
The Vanguard Group, Inc.
2.86%
Geode Capital Management, L.L.C.
1.86%
Equitec Proprietary Markets, LLC
1.22%
Asher (Daniel B)
1.22%
Outro
85.08%
Tipos de investidores
Investidores
Proporção
Corporation
7.76%
Investment Advisor
4.83%
Individual Investor
2.88%
Investment Advisor/Hedge Fund
2.44%
Hedge Fund
1.16%
Bank and Trust
0.05%
Outro
80.88%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
61
576.91K
8.49%
-485.34K
2025Q2
66
1.28M
18.72%
-522.91K
2025Q1
71
1.30M
18.90%
-631.78K
2024Q4
75
1.52M
21.80%
-704.25K
2024Q3
81
1.75M
23.16%
-1.87M
2024Q2
84
1.91M
21.34%
-3.77M
2024Q1
81
1.85M
20.70%
-3.82M
2023Q4
82
1.98M
21.84%
-3.87M
2023Q3
81
2.90M
23.35%
-2.45M
2023Q2
83
2.99M
16.94%
-4.58M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Intracoastal Capital, L.L.C.
527.38K
1.12%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
194.45K
0.41%
-71.00
-0.04%
Jun 30, 2025
Geode Capital Management, L.L.C.
126.60K
0.27%
-12.33K
-8.88%
Jun 30, 2025
Equitec Proprietary Markets, LLC
82.73K
0.18%
--
--
Jun 30, 2025
Asher (Daniel B)
82.73K
0.18%
--
--
Dec 31, 2024
Schechter (Jonathan L)
50.00K
0.11%
--
--
Sep 15, 2025
Silverman (Joshua N.)
50.00K
0.11%
--
--
Sep 15, 2025
Renaissance Technologies LLC
49.80K
0.11%
+300.00
+0.61%
Jun 30, 2025
Susquehanna International Group, LLP
27.61K
0.06%
+9.20K
+49.98%
Jun 30, 2025
Schonfeld Strategic Advisors LLC
26.20K
0.06%
+700.00
+2.75%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI